-
2024-517099-39-00
4
2024-11-18
Newly diagnosed transplant ineligible multiple myeloma
-
2024-513219-29-00
5
2024-10-21
Renal Cell Carcinoma
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2023-503322-39-00
3
2023-06-16
Newly diagnosed patients with metastatic (other than lung/pleura metas
-
2023-510275-64-00
9
2023-05-31
Hepatocellular carcinoma, colorectal cancer, endometrial
cancer, or ot
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2024-510575-38-00
10
2026-02-24
Relapsed and refractory mature B-cell non-Hodgkin Lymphoma
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2024-518385-26-01
5
2025-12-18
Polymyalgia Rheumatica (PMR)
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2023-510568-11-00
9
2025-11-18
High grade brain tumors
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-514110-12-00
7
2025-10-22
Thyroid Eye Disease
-
2025-521504-22-00
4
2025-10-16
Vitiligo
-
2023-510558-18-00
4
2025-10-13
locally advanced head and neck squamous cell carcinoma
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-512412-22-00
5
2025-06-24
Hemolytic Uremic Syndrome
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-515793-27-01
5
2025-04-30
HIV
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2022-502972-22-00
5
2024-10-31
Clostridioides difficile infection.